Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery

Brief Summary

Official Title: “Exparel (Bupivacaine Liposome Injectable Suspension) for Distal Upper Extremity Blocks in Orthopedic Surgery”

The purpose of this study is to compare Exparel, a new, long-lasting numbing medication and a shorter-acting nerve block to a traditional single-shot nerve block in patients having hand, wrist or finger surgery.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment
  • Study Primary Completion Date: March 2016

Interventions Used in this Clinical Trial

  • Drug: Exparel Forearm block
    • 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
  • Drug: Bupivacaine supraclavicular block
    • 20-30mL 0.5% bupivacaine

Arms, Groups and Cohorts in this Clinical Trial

  • Experimental: Exparel forearm block
    • Under ultrasound guidance, 3-5 mL Exparel will be injected around the 3 nerves of the forearm prior to surgery. 20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
  • Active Comparator: Bupivacaine supraclavicular block
    • Under ultrasound guidance, 20-30 mL 0.5% Bupivacaine will be used for the supraclavicular block.

Outcome Measures for this Clinical Trial

Primary Measures

  • Onset of Sensorimotor block
    • Time Frame: 30 minutes
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • patients 18 years or older having hand, wrist, or finger surgery
  • ability to understand and provide informed consent
  • American Society of Anesthesiologists status I-III
  • presence of a responsible adult caregiver for 48-72 hours after surgery

Exclusion Criteria

  • patient refusal or inability to provide informed consent
  • true allergy, not sensitivity to local anesthetics, midazolam, fentanyl, hydromorphone, propofol
  • pregnancy
  • hepatic or renal failure
  • evidence of infection at or near the proposed needle insertion site
  • any sensorimotor deficit of the upper extremity
  • BMI greater than or equal to 35
  • uncontrolled or severe pulmonary disease
  • anticoagulant use (not aspirin or non-steroidal anti-inflammatories)
  • chronic pain patients

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: Accepts Healthy Volunteers

Clinical Trial Investigator Information

  • Lead Sponsor
    • Jose Soberon, MD
  • Collaborator
    • Pacira Pharmaceuticals, Inc
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Jose Soberon, MD, Anesthesiologist – Ochsner Health System
  • Overall Official(s)
    • Jose Soberon, MD, Principal Investigator, Ochsner Clinic Foundation


Clinical Trials content is provided directly by the US National Institutes of Health via and is not reviewed separately by Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: